Oral Treatment of Hemophilia

This invention portrays a simple method for treatment of antigen-deficiency diseases by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. This method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.

Potential Commercial Applications: Competitive Advantages:
  • Oral-based treatment for hemophilia A or B
  • Less invasive than current modes of treatment
  • Reduced inflammatory response
  • Immunotolerization against future bleeding episodes

Development Stage:
  • In vitro data available
  • In vivo data available (animal)


Oral Alpan (NIAID)  ➽ more inventions...

Tirumalai Kamala (NIAID)  ➽ more inventions...

Polly Matzinger (NIAID)  ➽ more inventions...

William Velander

Intellectual Property:
US Pat: 7,220,718 issued 2007-05-22
US Pat: 7,867,974 issued 2011-01-11
PCT Application No. PCT/US02/24544 filed on 2002-08-02

Licensing Contact:
Charles Rainwater,
Email: crainwater@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: E-281-2001-0
Updated: Dec 4, 2013